

CLAIM AMENDMENTS

1. (currently amended) A selective chemotherapy method which includes the step of contacting tumor cells with a composition comprising:

(a) a plasma-soluble metal salt of ascorbic acid; and

(b) one or more Vitamin C metabolites selected from the group consisting of

(i) aldonic acids, the aldono-lactones, aldono-lactides and non-toxic metal salts of thereof, and

(ii) dehydroascorbic acid, threose, erythreose, 4-hydroxy-5methyl-3(2H)-furanone, 3-hydroxykojic acid and 5-hydroxymaltol.

2. (cancelled) A composition comprising the chemotherapeutic composition of Claim 1 in a pharmacologically acceptable intravenous carrier.

3. (cancelled) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is an aldonic acid.

4. (previously presented) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is a non-toxic metal salt of an aldonic acid.

5. (cancelled) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is an aldono-lactone.

6. (cancelled) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is a non-toxic metal salt of an aldono-lactone.

7. (cancelled) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is an aldono-lactide.

8. (cancelled) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is a non-toxic metal salt of an aldono-lactide.

9. (cancelled) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is dehydroascorbic acid.

10. (cancelled) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is threose.

11.(cancelled) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is erythreose.

12. (cancelled) The selective chemotherapy method of Claim 1 wherein said vitamin C metabolite is 4-hydroxy-5-methyl-3(2H)-furanone.